We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Pneumococcal Immune Status Accurately Determined in Saliva Samples

By LabMedica International staff writers
Posted on 27 Dec 2016
Measurement of levels of antibodies against 12 Streptococcus pneumoniae antigens in saliva was shown to provide as accurate an indication of immune status against this organism as was determination of antibody levels in blood serum.

The objective of a study carried out at the University of Birmingham United Kingdom) was to assess if levels of anti-pneumococcal (Pn) antibodies in saliva reflected concentrations in serum and to determine whether saliva could accurately identify protective concentrations in serum.

Toward this end the investigators employed a multiplex assay, the BioRad Laboratories (Hercules, CA, USA) Luminex-200, Bioplex System, that simultaneously measured antibody concentrations against 12 Pn antigens, to determine IgG, IgA, and IgM antibody levels in paired saliva and serum samples against 12 Pn polysaccharide antigens in 72 healthy adults.

Results revealed that antibody levels in saliva correlated positively with serum across immunoglobulin classes, most strongly for IgA. More...
Individuals who had protective antibody levels in serum demonstrated significantly higher IgG and IgA salivary antibody concentrations and secretion rates. Salivary IgG and IgA Pn antibodies were able to distinguish between those with/without protective levels in serum for the majority of serotypes. Salivary IgM antibodies were not able to differentiate protective status.

First author Dr. Jennifer Heaney, a researcher in immunity and infection at the University of Birmingham, said, "Protection against bacterial infection is usually inferred by measuring antibody levels in blood serum. But taking blood samples involves a number of logistical considerations and may not always be feasible, especially in developing countries or where children are involved. Saliva sampling is non-invasive, requires no specialist training or equipment, and may be more cost-effective. The suggestion that antibody levels in saliva may be indicative of those in serum therefore has important implications for markers of immunity and vaccination in many parts of the world. This research highlights the need for larger studies further to investigate the potential of saliva testing as a tool to assess immunity."

The study was published in the December 12, 2016, online edition of the journal Biomarkers.

Related Links:
University of Birmingham
BioRad Laboratories


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.